本文選題：髓勞病　切入點：貧血　出處：《黑龍江中醫(yī)藥大學》2017年碩士論文　論文類型：學位論文

【摘要】：目的:采用補腎生血法對30例慢性髓勞病患者治療6個月,通過外周血象、中醫(yī)證候積分等數(shù)據(jù)的療前、療后對比,觀察補腎生血法治療慢性髓勞病的臨床療效及療前療后骨髓中Kv1.3mRNA表達水平的差異性變化,并與10位志愿者組成的健康對照組進行對比,以了解慢性髓勞病患者Kv1.3mRNA表達水平與正常人之間的差異性。探討Kv1.3mRNA表達水平變化與慢性髓勞病發(fā)病機制之間可能存在的關(guān)系,從而推測補腎生血法治療慢性髓勞病可能存在的的療效機理。方法:①選擇30位已確診的慢性髓勞病患者為治療組,采用補腎生血法對這些患者進行為期6個月的治療,觀察并記錄這些患者的臨床療效、中醫(yī)證候積分及外周血象等在治療前后的變化;②采集這些患者用補腎生血法治療前后的骨髓,采用RT-PCR法檢測骨髓液中Kv1.3mRNA表達水平治療前后的變化。結(jié)果:①患者經(jīng)補腎生血法治療的臨床有效率為80.0%,患者經(jīng)補腎生血法治療六個月后癥狀均有明顯好轉(zhuǎn),中醫(yī)證候積分較療前也顯著降低,差異有統(tǒng)計學意義(P0.05);②治療后患者外周血血象各項指標明顯升高,差異有統(tǒng)計學意義(P0.05);③患者骨髓中Kv1.3mRNA表達水平在經(jīng)過補腎生血法治療六個月后,表達水平明顯上升,但仍低于健康對照組骨髓中Kv1.3mRNA的表達水平,差異均有統(tǒng)計學意義(P0.05)。結(jié)論:①補腎生血法對于慢性髓勞病的臨床治療具有肯定意義,無論在降低中醫(yī)證候積分、改善中醫(yī)證候、還是提高外周血象等方面都取得了顯著的療效。②慢性髓勞患者Kv1.3mRNA表達水平的低表達狀態(tài)可能與慢性髓勞的病機存在某種關(guān)系。③補腎生血法可能通過調(diào)節(jié)Kv1.3mRNA表達水平而調(diào)節(jié)整合素介導的造血微環(huán)境損傷,從而提高骨髓造血能力,促進造血干/祖細胞的增殖分化,最終達到治療慢性髓勞病的目的。
[Abstract]:Objective: to treat 30 patients with chronic pulpitis for 6 months by tonifying the kidney and generating blood, and to compare the data before and after treatment with the data of peripheral blood picture and TCM syndromes integral, etc. To observe the clinical effect of tonifying kidney and blood generating method in treating chronic myellabour disease and the difference of Kv1.3mRNA expression in bone marrow after treatment, and to compare it with the healthy control group composed of 10 volunteers. In order to understand the difference between the expression of Kv1.3mRNA in patients with chronic myellabour disease and normal subjects, and to explore the possible relationship between the changes of Kv1.3mRNA expression and the pathogenesis of chronic myellabour disease. Thus, the possible therapeutic mechanism of tonifying the kidney and generating blood was speculated. Methods 30 patients with chronic myellabour disease were selected as the treatment group and treated for 6 months with the method of tonifying kidney and generating blood. Observe and record the clinical curative effect of these patients, TCM syndromes integral and peripheral blood image changes before and after treatment to collect the bone marrow of these patients before and after treatment with the method of tonifying kidney and generating blood. RT-PCR method was used to detect the changes of Kv1.3mRNA expression in bone marrow fluid before and after treatment. Results the clinical effective rate of Bushen Shengxue therapy was 80.00.The symptoms of the patients treated with Bushen Shengxue method for six months were obviously improved. The score of TCM syndromes was also significantly lower than that before treatment. The difference was statistically significant (P 0.05). After treatment, the indexes of peripheral blood were significantly increased, and the level of Kv1.3mRNA expression in bone marrow of patients with P0.05 + 3 was significantly increased after six months of treatment with Bushen and Xue. The expression level of Kv1.3mRNA in bone marrow of healthy control group was significantly higher than that of healthy control group (P 0.05). Conclusion the method of tonifying kidney and generating blood by 1% 1 has positive significance for the clinical treatment of chronic Myelopathy, regardless of decreasing the integral of TCM syndromes. Improve TCM syndromes, The low expression level of Kv1.3mRNA in patients with chronic myelosis may have some relationship with the pathogenesis of chronic myelosis. 3 the method of tonifying kidney and generating blood may regulate the water expression of Kv1.3mRNA. Mediating integrin mediated hematopoietic microenvironment injury, Thus, the hematopoiesis ability of bone marrow was improved, and the proliferation and differentiation of hematopoietic stem / progenitor cells were promoted.
【學位授予單位】：黑龍江中醫(yī)藥大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R259

【參考文獻】

相關(guān)期刊論文 前10條

1 李靜;賈國榮;劉學文;;再生障礙性貧血的發(fā)病機制的研究進展[J];中國實驗診斷學;2017年01期

2 李乃謙;;熟地黃活性成分藥理作用的研究進展[J];中國處方藥;2017年01期

3 劉佳;趙海平;李春義;;鹿茸成分研究進展[J];特產(chǎn)研究;2016年04期

4 王亞非;李運海;邢姝琴;李彥;伊力扎提;商曉迪;趙東方;柏立群;;巴戟天有效成分及其治療腎陽虛證的研究進展[J];中華中醫(yī)藥雜志;2016年12期

5 李欽;胡繼宏;高博;李海東;宋爽;楊麗霞;;黃芪多糖在免疫調(diào)節(jié)方面的最新研究進展[J];中國實驗方劑學雜志;2017年02期

6 徐亞文;滕瑛鈺;劉奇峰;劉大同;;劉大同教授從毒論治再生障礙性貧血[J];長春中醫(yī)藥大學學報;2016年03期

7 鄧婷;婁世鋒;;免疫抑制劑治療再生障礙性貧血的研究進展[J];現(xiàn)代醫(yī)藥衛(wèi)生;2016年11期

8 申攀;李剛;;王祥麒教授治療再生障礙性貧血經(jīng)驗[J];中醫(yī)研究;2016年05期

9 趙文靜;王歷;王芝蘭;旺建偉;常惟智;孫敏;柴劍波;曲苗;曹靜;;淫羊藿的藥理作用及臨床應(yīng)用研究進展[J];中醫(yī)藥信息;2016年02期

10 劉威;;雄激素與環(huán)孢素A治療再生障礙性貧血的對比分析[J];中國醫(yī)藥指南;2016年02期

，

本文編號：1626725